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Abstract 
Background: Patients and their families have become more active in healthcare systems and research. 
The value of patient involvement is particularly relevant in the area of rare diseases, where patients face 
delayed diagnoses and limited access to effective therapies due to the high level of uncertainty in market 
approval and reimbursement decisions. It has been suggested that patient involvement may help to 
reduce some of these uncertainties. This review explored existing and proposed roles for patients, 
families, and patient organizations at each stage of the lifecycle of therapies for rare diseases (i.e., 
orphan drug lifecycle). Methods: A scoping review was conducted using methods outlined by Arksey and 
O'Malley. To validate the findings from the literature and identify any additional opportunities that were 
missed, a consultative webinar was conducted with members of the Patient and Caregiver Liaison Group 
of a Canadian research network. Results: Existing and proposed opportunities for involving patients, 
families, and patient organizations were reported throughout the orphan drug lifecycle and fell into 12 
themes: research outside of clinical trials; clinical trials; patient reported outcomes measures; patient 
registries and biorepositories; education; advocacy and awareness; conferences and workshops; patient 
care and support; patient organization development; regulatory decision-making; and reimbursement 
decision-making. Existing opportunities were not described in sufficient detail to allow for the level of 
involvement to be assessed. Additionally, no information on the impact of involvement within specific 
opportunities was found. Based on feedback from patients and families, documentation of existing 
opportunities within Canada is poor. Conclusions: Opportunities for patient, family, and patient 
organization involvement exist throughout the orphan drug lifecycle. However, based on the information 
found, it is not possible to determine which opportunities would be most effective at each stage. 
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Exploring patient and family involvement
in the lifecycle of an orphan drug: a
scoping review
Andrea Young1*, Devidas Menon1, Jackie Street2, Walla Al-Hertani3 and Tania Stafinski1
Abstract
Background: Patients and their families have become more active in healthcare systems and research. The value of
patient involvement is particularly relevant in the area of rare diseases, where patients face delayed diagnoses and
limited access to effective therapies due to the high level of uncertainty in market approval and reimbursement
decisions. It has been suggested that patient involvement may help to reduce some of these uncertainties. This
review explored existing and proposed roles for patients, families, and patient organizations at each stage of the
lifecycle of therapies for rare diseases (i.e., orphan drug lifecycle).
Methods: A scoping review was conducted using methods outlined by Arksey and O’Malley. To validate the findings
from the literature and identify any additional opportunities that were missed, a consultative webinar was conducted
with members of the Patient and Caregiver Liaison Group of a Canadian research network.
Results: Existing and proposed opportunities for involving patients, families, and patient organizations were reported
throughout the orphan drug lifecycle and fell into 12 themes: research outside of clinical trials; clinical trials; patient
reported outcomes measures; patient registries and biorepositories; education; advocacy and awareness; conferences
and workshops; patient care and support; patient organization development; regulatory decision-making; and
reimbursement decision-making. Existing opportunities were not described in sufficient detail to allow for the level of
involvement to be assessed. Additionally, no information on the impact of involvement within specific opportunities was
found. Based on feedback from patients and families, documentation of existing opportunities within Canada is poor.
Conclusions: Opportunities for patient, family, and patient organization involvement exist throughout the orphan drug
lifecycle. However, based on the information found, it is not possible to determine which opportunities would be most
effective at each stage.
Keywords: Rare diseases, Orphan drugs, Patient involvement, Scoping review
Background
In recent years, patients have become active in healthcare
systems and research, which have increasingly recognized
the benefits of their involvement [1]. Such benefits include:
improving the credibility and relevance of research [2]; en-
hancing the translation of research results into clinical
practice; establishing more responsive services leading to
better outcomes of care [3]; and identifying benefits and
costs often missing from health technology assessments of
new therapies [4]. While recognized by all patient commu-
nities, they are particularly valued by those with rare dis-
eases, who experience significant challenges around their
care. Often, they face delayed diagnoses and limited access
to effective therapies, since decisions on market approval
and reimbursement are fraught with uncertainties [5].
These uncertainties arise from a lack of robust information
around 1) clinical benefit, 2) value for money, 3) potential
adoption/diffusion, and 4) affordability [6]. High quality
clinical trials are difficult to conduct in small patient popu-
lations where validated outcome measures are lacking [7],
and natural histories are poorly understood [8, 9]. These
therapies can also be extremely expensive, but in many
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cases, they represent the sole active treatment option for
conditions that are not only rare, but also life-threatening
or severely debilitating.
It has been argued that patients can play an important
role in reducing decision uncertainties [10]. In Canada,
the potential value of patient input is reflected in Health
Canada’s draft Orphan Drug Regulatory Framework,
which was originally proposed in 2012. The Framework
had two objectives: 1) providing Canadians with better,
timelier access to orphan drugs (i.e., drugs that treat rare
diseases) and 2) encouraging and facilitating clinical
research on rare diseases [5], both of which were to be
accomplished, in part, by incorporating patient involve-
ment throughout the orphan drug lifecycle (Fig. 1) [5].
However, the ways in which patients were to be involved
were not specified.
Objective
The objective of this review was to explore existing and
proposed roles for patients with rare diseases, their fam-
ilies, and patient organizations who represent them at
each stage of the orphan drug lifecycle.
Methods
A scoping review was conducted using the following 6
steps developed by Arksey and O’Malley [11, 12].
Identifying the research questions
Two research questions were developed: 1) what oppor-
tunities exist for patients, families, and patient organiza-
tions to become involved at each stage of the orphan
drug lifecycle, and 2) what opportunities have been pro-
posed for involving them? In this paper, ‘patient’ refers to
an individual living with a rare disease and ‘family’ refers
to a patient’s family member or loved one who provides
physical and emotional care.
Identifying relevant studies
Literature search
A search for relevant peer-reviewed literature published
in English between January 2000 and May 2017 was
conducted using the following databases: MEDLINE,
PubMed, The Cochrane Library, the Centre for Reviews
and Dissemination databases (DARE, NHS EED and
HTA), EMBASE, Web of Science, and EconLit. Search
terms included relevant controlled vocabulary (e.g.,
Medical Subject Headings (MeSH): Patient Preference,
Patient Participation, Consumer Participation) and key-
words (e.g., Patient Engagement and Patient Involvement).
These were combined with terms for medical technologies
(e.g., MeSH terms: Diffusion of Innovation and Biomedical
Technology), as well as rare diseases (Rare Diseases and
Orphan Drug Production). A search for grey literature
was also conducted using ProQuest Dissertations and
Theses, NHS Evidence, and Google. The electronic
searches were supplemented by a manual search of
reference lists of relevant papers. Full details of the
search terms and sources used are provided in (see
Additional file 1: Appendix A).
Review of regulatory and reimbursement decision-making
processes
Over the past decade, opportunities for and public aware-
ness of patient input into regulatory and reimbursement
processes (e.g., patient evidence submissions; membership
on advisory or decision-making committees) have in-
creased considerably. To capture such opportunities, the
websites of regulatory and reimbursement decision-making
bodies in 20 countries were reviewed. They represented
the top 20 Organization for Economic Co-operation and
Development (OECD) countries based on gross domestic
product (GDP) per capita with populations greater than 1
million people and socialized health insurance programs/
universal healthcare; thus, they were seen as relevant to the
Canadian context [13]. Four countries (Qatar, Kuwait, the
United Arab Emirates, and Israel) were initially included in
the review, but a preliminary search revealed a paucity of
information regarding decision-making processes on drugs
in these countries. They were replaced with the next four
OECD countries that fulfilled the inclusion criteria.
Twelve of the countries are members of the European
Union (EU), which hosts the European Medicines Agency
(EMA) [14]. Since it is compulsory for officially designated
orphan drugs to go through EMA, its centralized regula-
tory approval processes were reviewed.
Searches for additional information on decision-making
processes were performed using the Google search engine.
When opportunities for involvement were not well de-
scribed, emails were sent to the decision-making organiza-


















Fig. 1 The Lifecycle of a Drug
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Study selection
Literature eligibility criteria
Literature selection was completed by two reviewers
who independently scanned the titles and abstracts of
citations identified through the search. Studies were
included if they described the involvement of patients,
families, or patient organizations in any stage of the
orphan drug lifecycle. Documents produced by patient
organizations describing their work were also included.
Since this review focused on involvement of patients with
rare diseases, their families and patient organizations
throughout the orphan drug lifecycle, literature describing
“public”, “community” and “citizen” engagement, non-drug
technologies, or common diseases were excluded,. How-
ever, because a broad lifecycle approach was used, literature
describing activities applicable to both drug and non-drug
technologies (e.g. natural history registries) was included.
Papers describing patient involvement in individual clinical
decision-making with health care providers were excluded,
since this study focused on macro-level processes. Ab-
stracts, editorials and commentaries were excluded.
Decision-making process eligibility criteria
No eligibility criteria were applied to the review of
decision-making processes and all decision-making pro-
cesses identified were included in this review.
Charting the data
One reviewer (AY) extracted data from all of the in-
cluded papers using a standardized data extraction form.
A second reviewer (TS) extracted data from a random
sample (30%) of the included papers to assess reliability.
For each ‘opportunity’ identified, the following informa-
tion was extracted: description of the activity; country in
which it took place; type of disease; participants involved
(i.e., patients, families, or patient organizations); partici-
pants’ role; and the impact or outcome.
For each decision-making process identified, one re-
viewer (AY) extracted data on any aspects in which pa-
tients, families, or patient organizations were involved
(e.g., submitting a topic for consideration; membership
on advisory or decision-making committees). Each as-
pect was defined as an opportunity for involvement.
Collating, summarising and reporting the results
Thematic analysis and open coding methods were used
to explore the types of activities reported in each oppor-
tunity and identify categorical themes. Thematic analysis
involves the identification, analysis and reporting of pat-
terns through repeated handling of data [15]. Open cod-
ing is used to identify themes by breaking the data into
distinct parts and examining and comparing them to
identify similarities and differences [16]. Where there ap-
peared to be overlap among themes, a decision was
made to keep them separate if combining them would
result in the loss of an important concept or idea. For
example, the theme of “Conferences and Workshops”
overlaps with “Advocacy and Awareness”. While ‘advo-
cacy’ may take place at conferences, it is not necessarily
the main purpose of such events. Opportunities were
also categorized as either existing (i.e., has taken place)
or proposed (i.e., is suggested for the future).
Consultation exercise
Members of the Patient and Caregiver Liaison Group of a
Canadian research network (Promoting Rare-Disease Inno-
vations through Sustainable Mechanisms or PRISM [17])
were invited to participate in a webinar to validate the find-
ings of the review and identify any additional opportunities
that were missed. These individuals were either patients
with rare disease patients or family members. The webinar
began with a brief introduction and description of the
review methodology. Subsequently, participants were pre-
sented with existing and proposed opportunities for pa-
tients, families and patient organizations (in that order)
under each theme. They were invited to comment on the
results and asked if they knew about any other existing or
proposed opportunities. Following the webinar, participants
were contacted individually for clarification or additional
information as needed.
Mapping opportunities onto the orphan drug lifecycle
Opportunities for involvement were mapped onto the or-
phan drug lifecycle by considering the stage at which each
opportunity might take place. Two maps were created,
one reflecting opportunities identified in the literature/
website review and the second reflecting the additional
opportunities identified in the webinar.
Results
The results of the literature search and review of websites
of regulatory and reimbursement processes are summa-
rized in Appendices A and B, respectively (Additional file
1: Appendix A and Additional file 2: Appendix B). Seventy-
three published studies, eleven grey literature documents,
and sixty-six webpages were reviewed. Existing and pro-
posed opportunities for involvement fell into 12 themes:
research outside of clinical trials; clinical trials; patient
reported outcome measures; patient registries and biore-
positories; stakeholder relationships and collaborations;
education; advocacy and awareness; conferences and
workshops; patient care and support; patient organization
development; regulatory decision-making; and reimburse-
ment decision-making. Definitions of each theme can be
found in Table C-1 (Additional file 3: Appendix C).
A summary of the most commonly identified oppor-
tunities follows.
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Existing opportunities for involvement in the orphan drug
lifecycle (Table 1)
Research
Individual patients and their families have contributed to
strategic directions for research through membership on
research priority-setting committees and participation in
priority-setting exercises [18]. They have also provided in-
put into non-clinical studies aimed primarily at under-
standing the experience of patients and families living with
rare diseases. In contrast, roles for patient organizations
have mainly involved the collection and synthesis of infor-
mation from their members (e.g. evaluating the effective-
ness of new orphan drugs for organization members [19]).
Clinical trials
Patient opportunities have solely comprised enrollment
in clinical trials as study subjects [20]. However, patient
organizations have contributed in multiple ways, includ-
ing providing input into trial design and helping to re-
cruit trial participants through communication of trial
information to members [21–24].
Patient reported outcome measures
Patient reported outcome measures (PROMs) are self-
reported measurement instruments designed to provide
information on aspects of health status relevant to a pa-
tient’s quality of life, including symptoms, functionality,
and physical, mental, and social health [25]. To date, the
role of patients and families in PROMs has predomin-
antly been in the development and validation of such
measures (e.g. consulting patients when formulating
questions for PROM survey [26–28]). Patient organiza-
tions have then managed the distribution of such surveys
to patients and families [29].
Patient registries and biorepositories
Patients and families have contributed to registries (pre-
dominantly natural history) through their enrollment and
submission of data [24, 30–37]. Many of the registries
have been established by patient organizations, in collab-
oration with researchers and healthcare professionals
[19, 32, 34, 37–41].
Stakeholder relationships and collaborations
On an individual level, patients and families have estab-
lished informal relationships with researchers [35, 42]. In
contrast, patient organizations have established formal
relationships with stakeholders or facilitated relationships
between stakeholder groups (e.g. by developing charters
for collaboration [21]).
Education
Patients and families have helped develop training pro-
grams for patients/families by identifying key content areas
[43, 44]. More opportunities were reported for organiza-
tions which have been involved in sharing informational
resources with patients, families, and health care profes-
sionals, often through websites, toll-free hotlines, and men-
toring programs [22–24, 40, 45–47]. They have also
organized formal educational activities for families (e.g. par-
ent training programs [44]) and health care professionals
(e.g. Grand Rounds [22]).
Advocacy and awareness
While ‘advocacy’ by patients and families has mainly in-
volved the use of social media to press for improved access
to drugs [48], in patient organizations it has comprised a
variety of efforts (e.g. lobbying for public funding; testifying
before Congressional committees) spanning drug coverage
[22], research [42] and legislation on rare diseases and or-
phan drugs [47, 49].
Conferences and workshops
Patients and families have participated in conferences and
workshops (e.g. helping identify goals for a national rare
disease strategy), while patient organizations have also
hosted and funded them [23, 24, 34, 35, 40, 49].
Patient care and support
Some patients and families have been able to provide in-
put into their care because they have had access and the
ability to update, their electronic health records, which
are reviewed by health care providers [50]. They have
provided input into patient care more broadly through
their participation in the development of clinical practice
guidelines [51, 52].
With respect to social support, individual patients and
families have built connections and shared information
through online fora (e.g. Patients Like Me [53]) developed
mostly by patient organizations (e.g. Muscular Dystrophy
Charity [54]). Patient organizations have also provided so-
cial support through social events and mentoring pro-
grams [22, 40, 45, 49, 55].
Patient organization development
Patients and families have created patient organizations
(e.g. French Muscular Dystrophy Organization [56]) which,
in turn, have provided advice to others who wish to estab-
lish them [57].
Regulatory decision-making
Patients and families have mainly contributed indirectly
to regulatory processes by reporting on adverse events
[58–63] or providing input on proposed regulatory guide-
lines [64–68]. However, patient organizations have been
more directly involved, with opportunities to serve on
decision-making/advisory committees [69, 70].
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Countries Patients and families Patient organizations













• Participated as research subjects (International
[132]; Denmark [133]; Japan [134]; Spain [93]; United
Kingdom [94, 133, 135]; United States [35, 136])
• Set research priorities (Netherlands [137, 138];
Spain [18])
• Initiated research studies (United States [19, 57])
• Provided assistance to researchers conducting
studies (Europe [139]); United States [140])
• Led research (International [53]; United States
[19, 141])
• Developed or participated in research
organizations/networks (Europe [142]; United
States [143])
• Disseminated research-related information
(International [144]; United Kingdom [54])
• Participated as research subjects (Europe [96])
• Set research priorities (Germany [42]; Netherlands
[137])
• Initiated research (Netherlands [42]; United States
[145])
• Provided assistance to researchers conducting
studies (International [30, 146]; Netherlands [137];
Spain [93]; United States [19])
• Led research (Europe [45]; France [56]; Ireland [146];
United Kingdom [97]; United States [19, 24, 40, 141])
• Participated in research organizations/networks
(Europe [142, 147]; Netherlands [42, 46]; United
States [39, 47, 143, 148])
• Disseminated research-related information
(International [144]; United Kingdom [54])
• Funded research (International [149]; Germany
[42]; United States [34, 35, 40, 47, 49, 143])





• Participation in trials [20] • Provided assistance to researchers conducting
trials (Europe [21]; Netherlands [46]; United States
[21])
• Funded clinical trials and clinical trial networks
(Europe [150]; United States [23])
• Established and/or participated in clinical trial
networks (Europe [150]; United States [23, 24, 47])
• Disseminated information on the results of clinical
trials (United States [23, 24])




• Submitted patient reported outcomes (PROs) in
studies (International [32])
• Participated in studies to develop and validate
outcome measures (International [26, 151];
Germany [27]; United States [28])
• Assisted researchers conducting studies to
develop and validate outcome measures
(International [26])
• Assisted researchers in conducting studies to








• Patients and/or families enrolled in and
submitted data to registries/biorepositories
(International [29, 37]; Sweden [33]; United
Kingdom [152]; United States [24, 34–36])
• Provided input on registry/ biorepository design
(International [32]; Europe [147])
• Involved in maintenance and/or management
(Europe [153])
• Established registries (United States [41]); however,
this was usually done through a patient organization
• Established of registries (International [32]; Europe
[38]; United Kingdom [152]; United States [19, 34,
39–41])
• Provided input on registry/ biorepository design
(International [32]; Europe [147]; United States
[154, 155])
• Involved in maintenance and/or management
(International [156]; Europe [38, 153]; Italy [157];
United Kingdom [152])
• Provided funding (Europe [153]; United Kingdom
[152]; United States [154])
• Recruited participants (International [32, 156]; Italy











• Established and maintained relationships with
researchers (Netherlands [42]; United States [35])
• Facilitated relationships between different
stakeholders through charters for collaboration and
hosting neutral meetings (Europe [21]; United
States [47])
• Established relationships with stakeholders (e.g.
researchers, industry, healthcare professionals, and other
patient organizations) (European Union [96]; Italy [157];
Netherlands [42]; United States [23, 35, 40, 47])




• Helped to develop educational material and
training programs for patients and families
(Europe [43]; Italy [44])
• Shared informational resources on various
disease-specific topics (Europe [45]; Netherlands
[46]; United States [22–24, 40, 47])
• Organized and sponsored formal educational
activities and training programs for healthcare
professionals, researchers and policymakers (United
States [22–24, 34, 49])
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• Used social media to advocate for access to
experimental drugs (United States [48]).
• Advocated for drug access and coverage (United
States [22])
• Advocated for research (Europe [38]; Germany [42])
• Advocated for legislation (United States [47, 49])





• Participated in conferences and workshops,
helping to identify goals and produce
recommendations for a national rare diseases
strategy (Australia [95])
• Participated in conferences and workshops aimed
at developing a national rare diseases strategy
(Australia [95])
• Hosted and funded multi-stakeholder conferences









• Provided social support for other patients
(International [53, 158]; United States [19, 140])
• Self-monitored clinical care through electronic
health records (Italy [50])
• Provided clinical care support by contributing to
the development of clinical practice guidelines
([51, 52]
• Provided social support (Europe [45]; United
Kingdom [22, 49]; United States [22, 40])
• Provided financial support (United Kingdom [22];
United States [22, 47])
• Provided clinical care support (Europe [38, 45];
United States [22, 34, 40])
• Provided support to patients in clinical trials







• Established patient organizations, like the French
Muscular Dystrophy Organization and
Chromosome 18 Registry and Research Society
(France [56]; United States [19])
• Provided advice to others on how to start an
organization (United States [57])
• Established international patient organization
alliances (International [156]; Netherlands [46];
United States [40])
• Further developed their organization by hosting











• Submitted PROs for consideration by a regulatory
body (Canada [65]; European Union [159]; New
Zealand [160]; United States [161])
• Provided input on proposed regulatory decisions/
guidelines (Canada [64, 65]; New Zealand [66];
United States [67, 68])
• Served as members on advisory/decision-making
committees (Canada [64, 65]; United States [67,
68])
• Provided input into assessments of benefits and
harms (United States [162])
• Reported adverse events to regulators (Australia
[58]; Canada [59]; European Union [60]; New
Zealand [61]; Switzerland [62]; United States [63])
• Representatives sat on advisory/decision-making
committees (European Union [69, 70])
• Provided input on pre-submission advice given to
researchers regarding clinical trial protocols (Euro-
pean Union [69])
• Provided input on assessments of benefits and
harms (European Union [60])
Provided input on plans for ongoing
pharmacovigilance (European Union [60])
• Provided input on consumer information, such as



















• Patients submitted drugs for evaluation (Australia
[75]; New Zealand [163])
• Submitted information for use in evaluations,
such as the degree of perceived benefit, subjective
risk assessment, or burden of associated side
effects (Netherlands [71]; New Zealand [72]; United
States [73])
• Participated in consultations during the review
process (Ontario [74]; New Zealand [72]; United
States [73])
• Served as members on advisory/decision-making
committees (Canada [164]; Netherlands [71])
• Provided feedback on completed evaluation
reports or recommendations (New Zealand [72];
United States [165])
• Prepared patient submissions for consideration
alongside clinical and economic evidence
(Australia [75]; United Kingdom [76]; Wales [77])
• Presented views during review committee
meetings (United Kingdom [87]; United States [73])
• Consulted on the design of the evaluation
process (United Kingdom [97])
Centralized review processes
• Reviewed horizon scanning reports (United
Kingdom [166])
• Submitted drugs for evaluation (Australia [167];
New Zealand [163])
• Participated in consultations during the review
process (Australia [168]; Germany [169]; United
Kingdom [87]; Scotland [170])
• Served as members on advisory/decision-making
committees (Sweden [171]; Switzerland [172];
United Kingdom [173]; United States [174])
• Prepared patient submissions for consideration
alongside clinical and economic evidence (Australia
[75]; Canada [175]; Ontario [74]; United Kingdom
[176]; Scotland [177]; Wales [77])
• Provided feedback on completed evaluation
reports or recommendations (Ontario [74])
• Launched appeals of negative funding decisions
(United Kingdom [97])
• Created recommendations for the design of the
evaluation process (United Kingdom [97])
Safety-net review processes
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Reimbursement decision-making
Opportunities for patient involvement in reimbursement
decision-making have mainly focussed on patient organi-
zations and included submission of information for use
in evaluations (e.g. degree of perceived benefit, subject-
ive risk assessment, or burden of associated side effects)
[71–73], participation in consultations during the review
process [72–74], and preparation of patient submissions
for consideration alongside clinical and economic evidence
[75–77]. Regarding patient submissions, similar processes
exist in Australia, Canada, and the United Kingdom. In
general, they involve completion of templates that ask
about 1) how information in the submission was obtained,
2) impact of the disease on patients, 3) experiences of pa-
tients with their current therapy, 4) expectations patients/
families for the new drug and 5) any patient experiences
with the new drug [78, 79]. In Canada, the submissions
also request information on family impact [78].
Opportunities for individual patients have also involved
participation in safety-net programs, which provide pa-
tients with access to unapproved or non-reimbursed drugs
on a case-by-case basis for a fixed time period [71, 80–89].
Individual patients and families have submitted drugs for
consideration by such programs [90], participated in con-
sultations during the review process [87], and presented
their views during committee meetings [87].
Despite the wide range of existing opportunities iden-
tified, none were described in sufficient detail to deter-
mine the level of involvement they represented using
published frameworks for engagement [91, 92]. These
frameworks often present involvement on a spectrum,
such as Arnstein’s ladder, which ranges from “manipula-
tion” (i.e. nonparticipation) to “citizen control” (i.e. citizen
power) [91]. Information on the impact of involvement in
specific opportunities was also limited. One study reported,
“[Patient involvement] was found to be particularly effect-
ive in enhancing the design and conduct of our research”
[93]. The remaining studies typically commented on the
success of an opportunity as whole (e.g. “the health utility
values provided by this study could inform assessments of
cost-effectiveness…” [94]).
Proposed opportunities for involvement
Proposed opportunities for involvement are presented
below. In general, they were described at a high level and
lacked information on the exact way in which patients,
families, or patient organizations should be involved.
Research
Participants attending the Australian Rare Disease Sympo-
sium suggested that patients and their families should be
directly involved in all decisions about research on rare
diseases, including involvement in the decision-making
processes of research collaborations and networks [95].
Clinical trials
Participants of the European Haemophilia Consortium
(EHC) Congress proposed that patients should be involved
in ensuring clinical trials collect real-world outcomes that
are meaningful to them [96]. In the United States, the
National Organization for Rare Disorders (NORD) pro-
posed that it should develop systems for improving patient
access to and participation in trials [47]. Finally, the
Genetic Alliance UK proposed that patient input on ac-
ceptable risk should be embedded into R&D of new treat-
ments, from drug design to clinical trials [97].
Stakeholder relationships and collaborations
One proposed opportunity for patients in the establish-
ment/ maintenance of relationships with stakeholders was
identified. The Genetic Alliance UK has called for im-
proved dialogue between patients, manufacturers, regula-
tory bodies, and clinical researchers to ensure alignment
between the data required for decision-making and the data
collected in clinical trials [97].
Patient care and support
The Genetic Alliance UK proposed that patients, in part-
nership with their physicians, should be responsible for
deciding if the benefits of using a new drug outweigh
the associated risks [97]. Families participating in a re-
search study proposed that those who have taken part in






Countries Patients and families Patient organizations
• Submitted drugs for consideration (Finland [90])
• Directly consulted during the review process
(United Kingdom [87])
• Provided feedback on evaluations or
recommendations (United Kingdom [87])
• Presented views during a committee meeting
(United Kingdom [87])
• Submit data for use in annual evaluations for
reapplications (Australia [178])
aIn addition to the website review
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clinical trials provide support for newly enrolled patients
and families [98].
Regulatory decision-making
Three organizations proposed opportunities for in-
volvement in regulatory decision-making. In the United
Kingdom, the Genetic Alliance UK suggested that patient
input on acceptable risk should be incorporated into
decision-making [97]. In Europe, participants in the EHC
Congress symposium proposed that patient representa-
tives should be added to advisory committees that do
not currently have representation [96]. In the United
States, NORD proposed that it should be involved in
1) identifying laws, regulations and policies that need
to be changed to encourage product approval [47]
and 2) establishing greater certainty in the orphan
product approval process, through consultations on
trial design and endpoint selection [47].
Reimbursement decision-making
At the EHC Congress’s Symposium, it was suggested
that patient input should be sought at an earlier stage in
the health technology assessment (HTA) process [96]
and that patient advocates and clinicians should work
together to create a shared consensus on the evaluation
of the efficacy and effectiveness of therapies [96]. In the
United Kingdom, the Genetic Alliance UK proposed four
potential roles for patient involvement in reimbursement
decision-making: presenting to the evaluation commit-
tee, consulting on the development of post-evaluation
research, providing input on any reassessment of risks
and benefits, and contributing to topic selection during
horizon scanning [97]. The Genetic Alliance UK also stated
that patient organizations should be formally involved in
drug identification and selection for reimbursement
decision-making [97]. In the United States, NORD pro-
posed that patient organizations work to assure reimburse-
ment of off-label drug use for rare disease patients [47].
Consultation exercise (feedback from patients and families)
Eight members of the PRISM Patient and Caregiver
Liaison Group participated in a webinar, during which
feedback on the above existing and proposed opportun-
ities was sought. Members represented a variety of dis-
ease types (e.g. cancer; non-cancerous tumor; blood,
metabolic; connective tissue; endocrine; lung; secretory
gland; and epileptic encephalopathies) and a range of ex-
perience within their disease communities. Five partici-
pants were patients and three were family members. All
eight were involved in patient organizations to some de-
gree (from new members to holding executive positions).
This allowed participants to speak from their perspective
as patients/family members and members of patient
organizations. Participants ranged in age from 18 to 70 years
and there were two males and six females. The session
lasted 2.5 h. In general, participants agreed with the find-
ings of the review, but identified some opportunities that
were not captured in the literature. They also clarified their
role in some of the opportunities that were identified.
These additions and clarifications are described below.
Research
Patients and families have fundraised for research, even
when there is no organization to represent them. Patients,
specifically, have also provided input on the format in
which they would like to receive a new drug, should it
come to market (e.g., pill vs. liquid).
Clinical trials
Patients and families differentiated between recruiting
patients to clinical trials and providing them with enough
information to make informed decisions on whether or
not to participate. They felt that while they had a role to
play in “providing all the information necessary so… pa-
tients know what options are out there in terms of re-
search” (Family member 2 (FM2)), it did not include
recruitment of participants.
Patient registries and biorepositories
Patients and families mentioned their involvement in rais-
ing funds to establish registries (without the support of an
organization) and using social media (e.g., Facebook) to
encourage enrollment. They also discussed some of the
challenges they have experienced, such as cost:
“…you’ve listed ‘establish and maintain registries’ but
a lot of organizations do not do that because it is too
expensive, too onerous.” – FM2.
To address these challenges, organizations are consider-
ing different types of registries, some of which involve
partnerships with industry or the academic community.
They have encouraged their members to participate in
registries established by industry and requested data from
these registries to share with the disease community.
Stakeholder relationships and collaborations
Patients and families indicated that some have been very
proactive about building relationships with stakeholders
outside of a patient organization, (individuals “can be the
link between stakeholders” (Patient 4 (P4)) (e.g., linking
fundraisers with patient organizations). They provided
examples of their own relationships with the government
through their local Members of Parliament (MPs) and
Members of the Legislative Assembly (MLAs).
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Education
Patients and families discussed a variety of work they
have done “as individual[s]… not through the patient
organization” (FM1) to provide education about their
disease to, not only other patients and families, but also
health care professionals. They have presented at Grand
Rounds in academic medical centres and participated in
standardized patient programs at universities, which has
helped to familiarize students in health-related fields
with different a range of rare medical conditions.
Advocacy and awareness
Patients and families believe “…there’s a time and place
for both [patients and patient organizations] to come in
and [do advocacy]…individual patients have done a lot
of individual advocacy work.” (P3). They have advocated
for access to new drugs well before social media existed
(e.g., meeting with their local MPs) and for improved
education, clinics, and patient care services. They have
also taken part in campaigns hosted by research organi-
zations, initiated their own campaigns (online and in
schools), and hosted fundraising events.
With respect to patient organizations, they have pro-
vided guidance to patients and families around how to
advocate for themselves, linked them with resources in
their community and written letters of support.
Conferences and workshops
Patients and families indicated that at conferences and
workshops, “…you have the expert patients who can
share their knowledge and give their perspective to other
patients or even to doctors and healthcare providers”
(P4). One participant had served on a planning committee
and organized opportunities for patient involvement (e.g.,
sitting on a panel) to ensure that these opportunities were
driven by actual patients. Another participant had volun-
teered at patient organization-hosted conferences, aiming
to help the conference run more smoothly and increase
involvement by assisting with aspects such as childcare.
Patient care and support
Patients and families felt that, as individuals, they provide
not “not just social support” (FM3), but also clinical care
support, helping other patients to identify appropriate treat-
ments and dosing. Patient organizations also offer clinical
care support through sharing information on treatments
and services available locally in each province/territory.
Regulatory decision-making
Participants mentioned that they had participated in a
webinar hosted by Health Canada, which described its
plans to “include patient involvement in regulatory
decision-making”. However, they “didn’t think it had gotten
very far on it…” (P3). No additional information on this
project was found.
Reimbursement decision-making
Participants described their own experiences with patient
evidence submissions to the common drug review (CDR)
in Canada. Many felt that the weight given to patient sub-
missions during decision-making, compared with other
sources of information (e.g., clinical trial data) was unclear.
“…I know very little about the weight it’s given. I don’t
think anybody knows the weight it’s given” – FM2.
Participants also described ways in which patient orga-
nizations have been involved in decision-making when
the CDR issues a negative recommendation. These in-
cluded media campaigns and meetings with government
officials in several provinces.
Other
Participants discussed the importance of sharing informa-
tion on specific ways in which they have been involved at
the different stages of the orphan drug lifecycle:
“…the patients and families who are involved in that
have to be ambassadors and get out there and show
the rest of the research community how it works and
how it was successful and what the impact was…we’re
trying to change a whole culture of how researchers
think and work…if they can get concrete examples of
how it’s worked in the past and how it’s been successful
and how it’s enhanced the research, they may be more
open to just having it proposed to them...” – P3.
This was seen as particularly important when patient
involvement was non-traditional (e.g. development of
equal partnerships with researchers conducting trials).
Mapping opportunities onto the orphan drug lifecycle
Opportunities for patients, families, and patient organi-
zations mapped onto the orphan drug lifecycle are pre-
sented in Table D-1 (Additional file 4: Appendix D). The
12 themes were then mapped onto the lifecycle in Figures
D-1 to D-3 (Additional file 4). These figures demonstrate
that opportunities for patients, families, and patient orga-
nizations exist throughout the lifecycle. In fact, nine of the
themes or categories of opportunities spanned the entire
lifecycle. They also illustrate gaps in the literature that
were subsequently filled through the webinar. Notably, al-
most none of the gaps related to opportunities for patient
organizations.
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Discussion
Through the literature review, an inventory of existing and
proposed opportunities for patients, families, and patient
organizations at each stage of the orphan drug lifecycle
was compiled. Further opportunities were identified by
webinar participants, demonstrating the need for greater
information-sharing of examples of patient and family in-
volvement in Canada. Members of the rare disease com-
munity have been engaged in a variety of roles throughout
the lifecycle of drugs for these diseases. However, there has
not been a standardized approach to their engagement. As
well, based on the literature the effects of this engagement
on drug development, approval, or funding are unclear,
since no evaluations have been done. Patients, families,
and patient organizations have also proposed additional
and increased roles for them in the lifecycle, suggesting
that they feel current levels of involvement are inadequate.
However, again, there is no framework proposed for a
more consistent and meaningful engagement.
This situation does not appear to be unique to rare dis-
eases. While no similar inventory of involvement oppor-
tunities for patients with common diseases could be found,
it has been acknowledged that, in general, efforts need to
be made to increase patient engagement in the research,
development, and approval of new drugs [99, 100]. For all
diseases, developing a drug that will improve patients’ lives
requires a deep understanding of their medical condition,
including their needs, preferences, and the trade-offs they
are willing to make. These insights can be gained through
improved patient involvement, leading to more relevant
and impactful patient outcomes and make drug develop-
ment faster, more efficient, and more productive. To this
end, researchers have worked to develop frameworks for
patient involvement in research [101–103] and the
pharmaceutical industry has proposed the development of
a “master framework” for integrated and systematic patient
involvement [99]. However, there are differences between
common diseases and rare diseases and it is reasonable to
expect that the need for and best approach to patient in-
volvement may differ between them. Given the nature of
rare diseases (i.e. low prevalence; disease heterogeneity),
clinical investigators often have less exposure to and un-
derstanding of the disease and its progression. As a result,
there is a greater chance of failing to capture what is im-
portant to patients. While this inventory may have some
relevant learnings for common diseases, it was compiled
with a focus on rare diseases and the specific challenges
associated with developing orphan drugs. With these
challenges in mind, the National Center for Advancing
Translational Sciences recently released their Toolkit
for Patient-Focused Therapy Development. Launched
in September 2017, the toolkit provides online resources
to patient organizations intended to help them advance
medical research on their disease (e.g. how to establish
a patient registry; how to conduct post-market sur-
veillance) [104].
This study has several limitations. The published pa-
pers, grey literature, and websites reviewed were limited
to English only. Additionally, with the exception of the
assessment of regulatory and reimbursement decision-
making processes, the results were limited to papers de-
scribing opportunities for rare disease patients only.
Therefore, some opportunities may have been missed. Fi-
nally, only one webinar was held, and it involved members
of a patient liaison group within a research collaborative.
Although actively engaged in Canada’s rare diseases com-
munity for many years, they may not have been familiar
with all opportunities for involvement.
Conclusion
There are a number of opportunities, both existing and
proposed, for patients, their families, and the organiza-
tions representing them to become involved in the orphan
drug lifecycle. However, based on the information found,
it is not possible to determine which opportunities would
be most effective at each stage of the lifecycle.
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